Loading...
•
Dec 31, 2025
Abbott Q4 2025 Earnings Report
Abbott reported solid Q4 results with earnings growth driven by margin expansion and strength in medical devices.
Key Takeaways
Abbott delivered a strong Q4, with adjusted EPS up and revenue rising over the prior year. Medical Devices led growth, while Diagnostics and Nutrition declined.
Q4 adjusted EPS rose to $1.50, driven by margin expansion and strong execution
Medical Devices led growth, with notable strength in Electrophysiology and Diabetes Care
Diagnostics revenue declined, impacted by lower COVID-19 test sales
Abbott guided for strong full-year 2026 growth in EPS and organic sales
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Abbott projects solid growth for FY 2026 with strong EPS and revenue outlook.
Positive Outlook
- FY26 adjusted EPS guidance of $5.55 to $5.80
- Expected organic sales growth between 6.5% and 7.5%
- Strong product pipeline and innovation across devices
- Continued margin expansion initiatives
- Growth expected in key emerging markets
Challenges Ahead
- COVID-19 testing sales continue to decline
- Diagnostics segment showed year-over-year contraction
- Nutrition segment still facing volume and pricing challenges
- Foreign exchange headwinds may impact growth
- Integration risks from Exact Sciences acquisition
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...